@article{behrens_strategic_2020,
 abstract = {Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the coronavirus disease 2019 (COVID-19) pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist.},
 author = {Behrens, Georg M. N. and Cossmann, Anne and Stankov, Metodi V. and Schulte, Bianca and Streeck, Hendrik and FÃ¶rster, Reinhold and Bosnjak, Berislav and Willenzon, Stefanie and Boeck, Anna-Lena and Thu Tran, Anh and Thiele, Thea and Graalmann, Theresa and Kayser, Moritz Z. and Zychlinsky Scharff, Anna and Dopfer, Christian and Horke, Alexander and Pink, Isabell and Witte, Torsten and Wetzke, Martin and Ernst, Diana and Jablonka, Alexandra and Happle, Christine},
 doi = {10.1007/s40121-020-00334-1},
 file = {Springer Full Text PDF:files/90/Behrens et al. - 2020 - Strategic Anti-SARS-CoV-2 Serology Testing in a Lo.pdf:application/pdf},
 issn = {2193-6382},
 journal = {Infect Dis Ther},
 language = {en},
 month = {December},
 number = {4},
 pages = {837--849},
 shorttitle = {Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting},
 title = {Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals},
 url = {https://doi.org/10.1007/s40121-020-00334-1},
 urldate = {2021-02-15},
 volume = {9},
 year = {2020}
}

